Literature DB >> 20447476

Boosting with mycobacterial heparin-binding haemagglutinin enhances protection of Mycobacterium bovis BCG-vaccinated newborn mice against M. tuberculosis.

Gloria G Guerrero1, Ann-Sophie Debrie, Camille Locht.   

Abstract

Heterologous prime-boost regimens are a valuable strategy to improve the generation of effector-memory T cell responses against intracellular pathogens. In this study we show that newborn mice vaccinated with bacillus Calmette-Guérin (BCG) and boosted with heparin-binding haemagglutinin (HBHA) had enhanced protective immunity against intranasal or aerosol Mycobacterium tuberculosis challenge over non-boosted mice, as evidenced by a considerable reduction of mycobacterial load in spleen and lung. The route of HBHA delivery had a differential impact on cytokine and antibody production in BCG-primed mice. The prime-boost regimen induced not only HBHA-specific IFN-gamma, but also other cytokines, such as IL-12 and TGF-beta, which may be associated with the generation of lung Th1 effector-memory lymphocytes, responsible for the enhanced protection against M. tuberculosis challenge.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447476     DOI: 10.1016/j.vaccine.2010.04.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Triggered Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin folding and dimerization.

Authors:  Joseph V Lomino; Ashutosh Tripathy; Matthew R Redinbo
Journal:  J Bacteriol       Date:  2011-03-11       Impact factor: 3.490

2.  Recombinant HBHA boosting effect on BCG-induced immunity against Mycobacterium tuberculosis infection.

Authors:  G G Guerrero; C Locht
Journal:  Clin Dev Immunol       Date:  2011-05-23

3.  Differential contribution of the repeats to heparin binding of HBHA, a major adhesin of Mycobacterium tuberculosis.

Authors:  Pierre Lebrun; Dominique Raze; Bernd Fritzinger; Jean-Michel Wieruszeski; Franck Biet; Alexander Dose; Mathieu Carpentier; Dirk Schwarzer; Fabrice Allain; Guy Lippens; Camille Locht
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

4.  MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice.

Authors:  Nacho Aguilo; Santiago Uranga; Dessislava Marinova; Marta Monzon; Juan Badiola; Carlos Martin
Journal:  Tuberculosis (Edinb)       Date:  2015-11-30       Impact factor: 3.131

5.  Construction of a DNA Vaccine Encoding Mtb32C and HBHA Genes of Mycobacterium tuberculosis.

Authors:  Roghayeh Teimourpour; Ali Sadeghian; Zahra Meshkat; Majid Esmaelizad; Mojtaba Sankian; Ahmad-Reza Jabbari
Journal:  Jundishapur J Microbiol       Date:  2015-08-29       Impact factor: 0.747

6.  IFN-α Boosting of Mycobacterium bovis Bacillus Calmette Güerin-Vaccine Promoted Th1 Type Cellular Response and Protection against M. tuberculosis Infection.

Authors:  C E Rivas-Santiago; G G Guerrero
Journal:  Biomed Res Int       Date:  2017-09-27       Impact factor: 3.411

7.  Proteomics for the Investigation of Mycobacteria.

Authors:  J A Bespyatykh; E A Shitikov; E N Ilina
Journal:  Acta Naturae       Date:  2017 Jan-Mar       Impact factor: 1.845

8.  A study on the immune response induced by a DNA vaccine encoding Mtb32C-HBHA antigen of Mycobacterium tuberculosis.

Authors:  Roghayeh Teimourpour; Hadi Peeridogaheh; Amir Teimourpour; Mohsen Arzanlou; Zahra Meshkat
Journal:  Iran J Basic Med Sci       Date:  2017-10       Impact factor: 2.699

Review 9.  Adjuvants: friends in vaccine formulations against infectious diseases.

Authors:  G G Guerrero Manriquez; I Tuero
Journal:  Hum Vaccin Immunother       Date:  2021-07-21       Impact factor: 4.526

10.  Immunogenicity of heparin-binding hemagglutinin expressed by Pichia pastoris GS115 strain.

Authors:  Xindong Teng; Xiaoguang Chen; Ke Zhu; Hefei Xu
Journal:  Iran J Basic Med Sci       Date:  2018-02       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.